The High Court of Judicature at Bombay has directed the Registrar of Trade Marks to remove the registration for the mark ‘LEFOXIN BIOX’ held by Shreya Life Sciences Pvt. Ltd., citing a likelihood of confusion with the established brand ‘LANOXIN’, owned by Glaxo Group Limited. In a ruling delivered on October 28, 2026, Justice Somasekhar Sundaresan determined that the registration, granted in December 2021, failed to account for the potential for error in the pharmaceutical sector, where both products are intended for medicinal use. The court has set a deadline of December 31, 2026, for the removal of the mark from the official register, granting the company a narrow window to initiate rebranding efforts.

The legal challenge was initiated by Glaxo Group under Section 57 of the Trade Marks Act, 1999. The petitioner argued that its ‘LANOXIN’ trademark, registered since 1956 for digoxin tablets used to treat cardiac failure and arrhythmia, enjoyed longstanding market recognition. In contrast, Shreya Life Sciences utilized the ‘LEFOXIN BIOX’ mark for levofloxacin, an antibiotic treatment for bacterial infections. Despite the significant clinical differences between the two drugs, the court emphasized that the broad classification of both marks within Class 5—covering medicinal and pharmaceutical preparations—necessitated a rigorous assessment of potential consumer confusion.

Justice Sundaresan’s reasoning underscored the principle that medicinal products require a stricter standard for trademark distinction. The judgment rejected the contention that the disparate therapeutic applications and the prescription-only nature of the drugs provided a sufficient safeguard against accidental substitution. “The test to be applied for adjudging the violation of trade mark law may not be on a par with cases involving non-medicinal products,” the court observed, noting that in the Indian context, factors such as phonetic similarity, visual appearance, and the potential for error by practitioners or patients must remain paramount.

Central to the court's decision was the comparison of the two marks as composite wholes. The judge concluded that ‘LEFOXIN’ functioned as the dominant element of the respondent’s mark, while the suffix ‘BIOX’ failed to offer enough distinctiveness to avoid an association with the petitioner’s brand. Furthermore, the court dismissed the argument that ‘OXIN’ was a common term in the pharmaceutical trade, noting that evidence regarding other levofloxacin brands did not support a general claim of publici juris. The court stated, “The addition of BIOX appears to indicate that the Impugned Mark is a variant of the Glaxo Mark.”

A significant aspect of the dispute involved the respondent's practice of manufacturing its antibiotic tablets in India exclusively for export to international markets. Shreya Life Sciences contended that because the goods were never sold domestically, no overlap existed between the consumers or trade channels. However, the court relied on Section 56(1) of the Trade Marks Act, which provides that the application of a trademark in India to goods intended for export constitutes "use" of the mark within the country. Consequently, the jurisdictional requirement for the rectification proceedings was satisfied, and the court affirmed that export-bound products are subject to the same regulatory scrutiny as domestic ones.

During the proceedings, the petitioner demonstrated that it became aware of the impugned registration in June 2024 following an investigation. The court evaluated the delay in filing the rectification petition and found no evidence of undue laches or acquiescence that would bar the petitioner from seeking relief. Justice Sundaresan noted that the petition was filed within the five-year timeframe stipulated by Section 33 of the Trade Marks Act. The court clarified that the absence of concrete proof of actual confusion did not preclude a finding of likelihood of confusion, which is the necessary threshold at the time of initial registration.

While the court acknowledged that the respondent’s adoption of the mark did not appear to be motivated by a malicious intent to imitate—characterizing it instead as a lack of diligence—the lack of dishonesty was ultimately irrelevant to the question of rectification. The court maintained that honest adoption is not a valid defense against the removal of a mark that is inherently prone to causing confusion. The judgment reaffirmed that the primary duty of the court in such matters is the protection of public health and the maintenance of the purity of the Trade Marks Register, rather than the balancing of private commercial interests.

The court’s direction for removal is prospective, aiming to facilitate an orderly transition for the respondent. Shreya Life Sciences is required to spend the remaining months of 2026 undertaking a comprehensive communications strategy to inform its stakeholders, international distributors, and regulators of the impending change. This period is also intended to allow the company to secure necessary regulatory approvals for a new brand name. The court indicated that these actions should be taken upon receipt of the official judgment, and all relevant government authorities are expected to assist in the processing of these administrative transitions.

By resolving the matter through a clear directive, the Bombay High Court has emphasized the high stakes involved in pharmaceutical branding. The decision reinforces that manufacturers, even those operating exclusively for export, must ensure that their intellectual property does not intersect with existing, well-established pharmaceutical marks. The judgment provides a roadmap for future rectification applications involving complex medical products, emphasizing that the burden of ensuring a distinct identity lies heavily with the entity seeking registration, regardless of the therapeutic profile of their specific formulation. The matter is now closed as the parties proceed to comply with the court's timeline for rebranding.